Equities

Precipio Inc

Precipio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.21
  • Today's Change0.00 / 0.00%
  • Shares traded43.00
  • 1 Year change-49.10%
  • Beta1.2882
Data delayed at least 15 minutes, as of May 16 2024 20:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.

  • Revenue in USD (TTM)15.81m
  • Net income in USD-4.90m
  • Incorporated1997
  • Employees51.00
  • Location
    Precipio Inc12325 Emmet StOMAHA 68164-4243United StatesUSA
  • Phone+1 (203) 787-7888
  • Fax+1 (302) 655-5049
  • Websitehttp://www.precipiodx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
3DX Industries Inc395.19k-688.11k1.90m0.00------4.81-0.0182-0.01820.0104-0.06530.4891--16.73---85.16-286.11----92.78---174.12-1,759.99---2.54-----2.83--19.39------
LumiraDx Ltd126.52m-338.03m3.29m1.21k------0.026-1.08-1.080.4021-1.310.27651.792.44104,557.90-73.83---96.82---80.48---267.03--1.01-10.512.14---39.62---343.67------
Signal Advance Inc800.00-234.65k3.41m0.00--1.94--4,259.32-0.0056-0.00560.000020.03810.0001-------3.9114.53-4.0815.13-----29,331.2573.68----0.00------11.34------
Thermogenesis Holdings Inc9.45m-17.98m4.14m25.00------0.4384-8.60-8.603.99-0.46080.6173.176.71377,800.00-123.58-78.08-369.62-133.9420.4429.01-200.31-133.660.3209-0.65531.88---9.90-0.4739-59.49--6.96--
Reflect Scientific Inc1.08m-459.04k4.21m7.00--2.23--3.90-0.0054-0.00540.01270.02210.42230.54679.10154,307.10-17.9511.10-21.0113.2155.2262.48-42.5010.002.34--0.00---47.09-6.99-613.46------
US Nuclear Corp2.14m-2.68m4.53m--------2.12-0.078-0.0780.063-0.03330.72260.57949.86---90.06-86.43---190.1447.7649.41-124.64-99.000.1018-0.63412.56---2.16-7.39-6.80------
Telesis Bio Inc24.63m-47.13m7.27m137.00------0.2953-28.31-28.3114.8012.940.32313.275.58179,802.90-59.34---67.10--60.43---183.66--3.08-35.890.2015--0.2697---1.14------
Precipio Inc15.81m-4.90m9.13m51.00--0.6953--0.5772-3.73-3.7311.608.930.877317.8517.93310,039.20-27.20-44.98-34.82-58.6839.1428.80-31.00-118.070.6201-350.950.0278--61.4639.6252.04--5.37--
Lifeloc Technologies Inc9.33m205.61k9.47m37.0046.051.4920.131.010.08380.08383.802.591.081.8412.96252,150.502.390.29812.760.340543.3040.752.200.32452.34--0.1611--9.992.03145.11-1.09-54.22--
Electro-Sensors Inc8.75m330.00k14.02m35.0042.561.0233.071.600.09610.09612.554.020.60952.487.03250,114.302.301.242.431.2949.1552.433.772.0215.41--0.00---5.252.68175.00--16.95--
Quarta-Rad Inc508.31k44.49k15.66m0.00353.3639.82345.7630.810.00280.00280.03240.02510.70743.0014.74--6.19-0.007111.98-0.015536.0732.788.75-0.00410.7347--0.00---53.81-10.96205.14------
Data as of May 16 2024. Currency figures normalised to Precipio Inc's reporting currency: US Dollar USD

Institutional shareholders

9.44%Per cent of shares held by top holders
HolderShares% Held
Kennedy Capital Management LLCas of 31 Dec 202339.50k2.78%
The Vanguard Group, Inc.as of 31 Mar 202435.52k2.50%
BlackRock Fund Advisorsas of 31 Mar 202428.91k2.04%
Geode Capital Management LLCas of 31 Dec 202314.35k1.01%
Walleye Capital LLCas of 31 Dec 202313.34k0.94%
Tower Research Capital LLCas of 31 Dec 20231.35k0.10%
Wells Fargo Advisors Financial Network LLCas of 31 Mar 2024550.000.04%
The Retirement Group LLC (California)as of 31 Mar 2024340.000.02%
Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024110.000.01%
Woodbury Financial Services, Inc.as of 31 Dec 202337.000.00%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.